Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 23 resultados

IPIE: Intelligent Assessment of Pharmaceutical in the Environment F. HOFFMANNLA ROCHE AG participó en un FP6: Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patie...
2015-01-01 - 2019-06-30 | Financiado

EPAD: European Prevention of Alzheimer’s Dementia Consortium F. HOFFMANNLA ROCHE AG participó en un FP6: Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression...
2015-01-01 - 2019-12-31 | Financiado

DRIVE-AB: DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE F. HOFFMANNLA ROCHE AG participó en un FP6: Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a f...
2014-10-01 - 2017-12-31 | Financiado

GETREAL: Incorporating real-life clinical data into drug development F. HOFFMANNLA ROCHE AG participó en un FP6: When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and effica...
2013-10-01 - 2017-03-31 | Financiado

EMIF: European Medical Information Framework F. HOFFMANNLA ROCHE AG participó en un FP6: In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected,...
2013-01-01 - 2018-06-30 | Financiado

K4DD: Kinetics for Drug Discovery (K4DD) F. HOFFMANNLA ROCHE AG participó en un FP6: There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for c...
2012-11-01 - 2017-10-31 | Financiado

STEMBANCC: Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) F. HOFFMANNLA ROCHE AG tramitó un FP6: StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug disc...
2012-10-01 - 2018-03-31 | Financiado

ETRIKS: Delivering European Translational Information & Knowledge Management Services F. HOFFMANNLA ROCHE AG participó en un FP6: Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive...
2012-10-01 - 2018-09-30 | Financiado

EU-AIMS: European Autism Interventions - A Multicentre Study for Developing New Medications F. HOFFMANNLA ROCHE AG tramitó un FP6: Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core sy...
2012-04-01 - 2018-03-31 | Financiado

QUIC-CONCEPT: QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy F. HOFFMANNLA ROCHE AG participó en un FP6: The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proli...
2011-09-01 - 2018-06-30 | Financiado

EHR4CR: Electronic Health Record systems for Clinical Research F. HOFFMANNLA ROCHE AG participó en un FP6: Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost press...
2011-03-01 - 2016-02-29 | Financiado

DDMORE: Drug Disease Model Resources F. HOFFMANNLA ROCHE AG participó en un FP6: Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD...
2011-03-01 - 2016-08-31 | Financiado

ONCOTRACK: OncoTrack - Methods for systematic next generation oncology biomarker development F. HOFFMANNLA ROCHE AG participó en un FP6: We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients wit...
2011-01-01 - 2016-12-31 | Financiado

IMIDIA: Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in... F. HOFFMANNLA ROCHE AG participó en un FP6: An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demi...
2010-02-01 - 2015-09-30 | Financiado

SAFESCIMET: European Modular Education and Training Programme in Safety Sciences for Medicines F. HOFFMANNLA ROCHE AG tramitó un FP6: Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has...
2010-01-01 - 2016-09-30 | Financiado

ETOX: Integrating bioinformatics and chemoinformatics approaches for the development of expert systems all... F. HOFFMANNLA ROCHE AG participó en un FP6: The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological pr...
2010-01-01 - 2016-12-31 | Financiado

PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... F. HOFFMANNLA ROCHE AG participó en un FP6: PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
2010-01-01 - 2015-12-31 | Financiado

SUMMIT: SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innovative diabetes Tools F. HOFFMANNLA ROCHE AG participó en un FP6: Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be...
2009-11-01 - 2015-10-31 | Financiado

EMTRAIN: European Medicines Research Training Network F. HOFFMANNLA ROCHE AG participó en un FP6: EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will es...
2009-10-01 - 2016-09-30 | Financiado

U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes F. HOFFMANNLA ROCHE AG participó en un FP6: RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado